Accéder au contenu
Merck
  • Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.

Ligustrazine derivatives. Part 3: Design, synthesis and evaluation of novel acylpiperazinyl derivatives as potential cerebrocardiac vascular agents.

Bioorganic & medicinal chemistry (2009-03-31)
Xian-Chao Cheng, Xin-Yong Liu, Wen-Fang Xu, Xiu-Li Guo, Ning Zhang, Yu-Ning Song
RÉSUMÉ

A series of novel acylpiperazinyl Ligustrazine derivatives was designed, synthesized, and their protective effects on damaged ECV-304 cells and antiplatelet aggregation activities were evaluated. The results showed that compound E33 displayed most potential protective effects on the ECV-304 cells damaged by hydrogen peroxide, and compound E1 was found to be the most active antiplatelet aggregation agent. Structure-activity relationships were briefly discussed.

MATÉRIAUX
Référence du produit
Marque
Description du produit

Sigma-Aldrich
2,3,5,6-tétraméthylpyrazine, natural, ≥98%, FG
Sigma-Aldrich
2,3,5,6-tétraméthylpyrazine, 98%
Sigma-Aldrich
2,3,5,6-tétraméthylpyrazine, ≥98%, FG